Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms
NCT01376349 · View on ClinicalTrials.gov ↗
Study Summary
RATIONALE: Dehydroepiandrosterone (DHEA) may help relieve vaginal symptoms in female cancer survivors. PURPOSE: This randomized phase III trial studies DHEA to see how well it works compared to placebo in treating postmenopausal cancer survivors with vaginal symptoms.
Conditions Studied
Interventions
- OTHER placebo
- DRUG prasterone
Study Locations (20)
Colorado
- Aurora Presbyterian Hospital — Aurora
- Boulder Community Hospital — Boulder
- Penrose Cancer Center at Penrose Hospital — Colorado Springs
- St. Anthony Central Hospital — Denver
- Porter Adventist Hospital — Denver
- Presbyterian - St. Luke's Medical Center — Denver
- St. Joseph Hospital — Denver
- Rose Medical Center — Denver
- CCOP - Colorado Cancer Research Program — Denver
- Swedish Medical Center — Englewood
- Poudre Valley Hospital — Fort Collins
- Front Range Cancer Specialists — Fort Collins
- North Colorado Medical Center — Greeley
- Littleton Adventist Hospital — Littleton
- Sky Ridge Medical Center — Lone Tree
- Hope Cancer Care Center at Longmont United Hospital — Longmont
- McKee Medical Center — Loveland
- Parker Adventist Hospital — Parker
- St. Mary - Corwin Regional Medical Center — Pueblo
Arizona
- Mayo Clinic Scottsdale — Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 464 participants |
| Start Date | 2011-07 |
| Est. Completion | 2017-11 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01376349
The ClinicalTrials.gov registry entry for NCT01376349 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 464 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 147 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions — of which placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT01376349 reports 20 study locations spanning 2 distinct geographic areas — top geographies include Colorado, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT01376349 about?
NCT01376349 is a clinical study titled "Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms". RATIONALE: Dehydroepiandrosterone (DHEA) may help relieve vaginal symptoms in female cancer survivors. PURPOSE: This randomized phase III trial studies DHEA to see how well it works compared to placebo in treating postmenopausal cancer survivors with vaginal symptoms.
What is the current status of trial NCT01376349?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 464 participants. The study started on 2011-07. Estimated completion is 2017-11.
What conditions does trial NCT01376349 study?
This clinical trial studies the following conditions: Breast Cancer, Gynecologic Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT01376349?
The interventions under investigation include: placebo (OTHER), prasterone (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT01376349?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 147 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT01376349 being conducted?
This trial has 20 study locations across Arizona, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.